Relypsa, Inc. RLYP saw a big move in the last trading session, as the company's shares fell by over 19% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $36.37 to $46.05 in the past one-month time frame.
This slump shouldn't be too much of a surprise to investors, as the company, a pharmaceutical firm specializing in non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases, has seen 3 negative revisions in the past few weeks and its current year earnings consensus has also moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
RLYP currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Medical- Generic Drugs industry may consider better-ranked stocks like Dr. Reddy's Laboratories Ltd. RDY, Mallinckrodt plc MNK and Actavis plc ACT. While Dr. Reddy's and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), Actavis carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ACTAVIS PLC ACT: Free Stock Analysis Report
MALLINCKRODT PL MNK: Free Stock Analysis Report
DOCTOR REDDYS RDY: Free Stock Analysis Report
RELYPSA INC RLYP: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Market News and Data brought to you by Benzinga APIsThis slump shouldn't be too much of a surprise to investors, as the company, a pharmaceutical firm specializing in non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases, has seen 3 negative revisions in the past few weeks and its current year earnings consensus has also moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
RLYP currently holds a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Medical- Generic Drugs industry may consider better-ranked stocks like Dr. Reddy's Laboratories Ltd. RDY, Mallinckrodt plc MNK and Actavis plc ACT. While Dr. Reddy's and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), Actavis carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ACTAVIS PLC ACT: Free Stock Analysis Report
MALLINCKRODT PL MNK: Free Stock Analysis Report
DOCTOR REDDYS RDY: Free Stock Analysis Report
RELYPSA INC RLYP: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
